Featured Research

from universities, journals, and other organizations

Scientists harness immune system to prevent lymphoma relapse

Date:
October 18, 2012
Source:
University of Manchester
Summary:
Scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.

UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.

The University of Manchester researchers, who were funded by the charities Leukaemia & Lymphoma Research and Cancer Research UK, have shown that, when used in conjunction with radiotherapy, the new drug is potentially four times more likely to lead to long-term survival than radiotherapy alone.

Relapse is a common fate for many lymphoma patients and new treatments are desperately needed. The new research, which is published online in Blood, the Journal of the American Society of Hematology (ASH), shows that the chemical R848 can be used to prime the immune system to fight cancer.

R848 is a chemical which signals to certain molecules known as receptors found on the surface of immune cells, triggering them into action. Receptors play a key role in the function of the immune cell by recognising harmful agents and instructing the cell to respond. It was shown that injections of R848 can generate a rapid expansion of specific anti-lymphoma immune cells known as 'killer T cells'.

Dr Simon Dovedi, of The University of Manchester's Institute of Cancer Sciences and the Manchester Cancer Research Centre, who conducted the research in the Targeted Therapy Group led by Professor Tim Illidge, said: "Excitingly we think that this new approach to treating cancer could be capable of giving patients a better response to conventional therapies through the generation of a lymphoma-specific immune response against tumour cells. This could be the key to ensuring long-term survival in more patients and reducing the number of relapses after initial therapy."

The Manchester team tested injections of R848, in combination with radiotherapy, in the laboratory on mice with lymphoma. It was found to have few side effects, with 100% of mice achieving long-term survival compared to just 28% of those mice which were treated with radiotherapy alone. In those mice that achieved long-term survival through treatment with R848 and radiotherapy, any re-introduction of cancer was completely rejected by the immune system in 75% of cases. These successful laboratory results mean that it could soon be used in early phase clinical trials for patients with lymphoma.

Professor Chris Bunce, Research Director of Leukaemia & Lymphoma Research, said: "While it is still early and this treatment has not yet been tested in humans, these results are hugely promising. One of the major obstacles to long-term successful treatment for many types of lymphoma has been relapse after initial successful treatment. Treatment with R848 can prime T cells to recognise various tumour-associated antigens, protecting patients from the return of the cancer."

Dr Kat Arney, Science Information Manager at Cancer Research UK, said: "Finding new ways to tackle lymphoma that has come back after treatment is vital if we're to beat this disease for good. Research is our best weapon against cancer, and we hope that this promising lab work will lead to more effective treatments for patients in the future."

The report is published online in the journal Blood, the Journal of the American Society of Hematology (ASH), under the title "Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma." Principal authors: Dr Simon Dovedi, Dr Jamie Honeychurch and Professor Tim Illidge of The Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester


Story Source:

The above story is based on materials provided by University of Manchester. Note: Materials may be edited for content and length.


Journal Reference:

  1. Simon J. Dovedi, Monique H.M. Melis, Robert W. Wilkinson, Amy L. Adlard, Ian J. Stratford, Jamie Honeychurch, and Timothy M. Illidge. Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma. Blood, 2012; DOI: 10.1182/blood-2012-05-432393

Cite This Page:

University of Manchester. "Scientists harness immune system to prevent lymphoma relapse." ScienceDaily. ScienceDaily, 18 October 2012. <www.sciencedaily.com/releases/2012/10/121018123050.htm>.
University of Manchester. (2012, October 18). Scientists harness immune system to prevent lymphoma relapse. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2012/10/121018123050.htm
University of Manchester. "Scientists harness immune system to prevent lymphoma relapse." ScienceDaily. www.sciencedaily.com/releases/2012/10/121018123050.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins